AstraZeneca stock holds near GBX11,263 support as regulatory approval for Benralizumab in India boosts confidence

Traders Union
All News
Financial News
AstraZeneca down 0.43% at GBX12,576 today

Highlights

AstraZeneca Pharma India secured CDSCO approval to import and distribute Benralizumab (Fasenra) for Hypereosinophilic Syndrome treatment in patients 12 and older.
This regulatory milestone expands AstraZeneca's specialty biologics portfolio in India, providing access to a niche patient segment with significant unmet needs.
AZN/GBX price is consolidating within a GBX11,271–13,880 range, with indicators signaling mixed momentum and a higher likelihood of downside movement near term.

Indian regulatory approval expands AstraZeneca's specialty biologics reach

AstraZeneca Pharma India received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell, and distribute Benralizumab (Fasenra) for patients aged 12 years and older diagnosed with Hypereosinophilic Syndrome (HES), according to Sahi. This regulatory clearance broadens AstraZeneca's product portfolio in India and grants access to a specialized patient population, enabling the company to address an area of unmet medical need. By increasing its presence in the specialty biologics market, AstraZeneca stands to benefit from new revenue opportunities in the region.

Bullish bias meets strong selling as technical signals diverge

AZN/GBX is trading above the MA-20 at GBX12,462, but remains below the MA-50 at GBX12,677 on the hourly chart and the MA-200 at GBX13,816 on the daily timeframe. Immediate technical support is provided by the Ichimoku Kijun at GBX11,263. The Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both point to strong selling pressure, while the Relative Strength Index (RSI) stands at 56.03 and registers a bullish reading. Momentum and oscillator signals are divergent, with the Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power all in overbought territory, highlighting buyer dominance but also suggesting stretched intraday conditions. The Awesome Oscillator is neutral, adding to the lack of clear short-term direction.

Consolidation expected as bearish risk outweighs bullish potential

Over the next two to three trading days, price action is likely to remain bound within a volatility band of GBX11,271 to GBX13,880. The probability of an upward move is estimated at 36%, while the chance of a downward scenario is 64%. The baseline outlook calls for a period of consolidation in a sideways corridor, with a bullish case requiring a decisive break above resistance to trigger further upside, and a bearish scenario opening up if immediate support is breached.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca’s new regulatory approval in India as a fundamental positive for its long-term presence. He notes that the news expands the company’s specialty portfolio and strengthens its regional growth prospects. However, he observes that technicals remain mixed, with price action still inside a consolidation range below major trend barriers. Karapetjanc believes risk-reward is improving, but the broader structure must stabilize. "If the support at GBX11,263 holds, I see AstraZeneca as well-positioned to benefit from its recent clinical approval and future upside catalysts."

Previously it was reported that AstraZeneca faced a period of sideways price action, with technical signals reflecting indecision despite ongoing portfolio expansion. The recent regulatory approval in India enhances AstraZeneca's regional growth prospects, and traders should monitor for a decisive breakout above resistance or a breach of support to determine the next directional move.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.